# of Displayed Technologies: 20 / 199

Applied Category Filter (Click To Remove): Life & Health Sciences


Categories

IDEAS: Revolutionizing Early Childhood Education with Automated Interaction Analysis
TS-065825 — The Need: In early childhood education settings, understanding children's interactions, both social and linguistic, is paramount for effective teaching and development monitoring. However, manual observation and analysis of these interactions can be time-consuming and subjective, hindering educa…
  • College: College of Education & Human Ecology
  • Inventors: Gonzalez Villasanti, Hugo "Hugo"; Justice, Laura
  • Licensing Officer: Dahlman, Jason "Jay"

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Schultz, Teri

Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
  • College: College of Medicine (COM)
  • Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
  • Licensing Officer: Schultz, Teri

Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes. The Need Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Targeted Nanobody Technology for Precise Antineoplastic Treatment
TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Palmieri, Dario; Ryan-Simkins, Michael
  • Licensing Officer: Willson, Christopher

Peptide-based inhibitor of host factor involved in HIV-1 replication
TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…
  • College: College of Arts & Sciences
  • Inventors: Musier-Forsyth, Karin; Tang, Yingke
  • Licensing Officer: Willson, Christopher

Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
  • College: College of Arts & Sciences
  • Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
  • Licensing Officer: Willson, Christopher

MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need: Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Dahlman, Jason "Jay"

Containment System for Heating and Off-Gassing
TS-065424 — Due to environmental concerns and the decreasing supply of fossil fuels, there is substantial demand for nuclear-based energy production. Nuclear energy now provides about 10% of the world's electricity from about 440 power reactors and is the second largest source of low-carbon power. In addition, over 50 smaller countries utilize nuclear energy in about 220 research-size reactors. These reactors are used to produce medical and industrial isotopes and several other purposes.
It is essential to meet the safeguard requirements in liquid-fueled molten salt reactors, fuel salt transportation, and fuel cycle processes and to develop effective methods for measuring and monitoring the mass of molten fuel salt or coolant salt. However, due to the complex and dynamic nature o…
  • College: College of Engineering (COE)
  • Inventors: Van Zile, Matthew; Cao, Lei Raymond; Kauffman, Andrew
  • Licensing Officer: Zinn, Ryan

Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells. The Need Current therapies…
  • College: College of Medicine (COM)
  • Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
  • Licensing Officer: Schultz, Teri

Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
  • College: College of Medicine (COM)
  • Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
  • Licensing Officer: Schultz, Teri

IR Precision: Revolutionizing Colorectal Cancer Metastasis Diagnosis with the CCML Library
TS-064834 — The Need: Colorectal cancer remains a significant global health challenge, particularly when it metastasizes to the liver. Accurate and rapid diagnosis of metastatic liver lesions is crucial for effective treatment planning and patient outcomes. Traditional diagnostic methods often lack the specific…
  • College: College of Arts & Sciences
  • Inventors: Coe, James; Allen, Heather; Bradley, Rebecca; Hitchcock, Charles; Martin, Edward
  • Licensing Officer: Willson, Christopher

Decision Support Tool for Prevention of Failure to Rescue Events
TS-064718 — A clinical decision support tool for minimizing failure to rescue events at hospitals.
Failure to rescue (FTR) is a serious issue in patient safety and healthcare quality for hospitalized patients. The term implies that rescue is possible, and death is, therefore, a failure. On any given day across the country, two-thirds of deaths in hospitals could be judged as preventable. In 2005,…
  • College: OSU Wexner Medical Center
  • Inventors: Garvey, Paula; Justice, Stephanie
  • Licensing Officer: Schultz, Teri

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Willson, Christopher

Magnetic Nanoparticles for Cancer Cell Classification
TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…
  • College: College of Arts & Sciences
  • Inventors: Schultz, Zachary; Rist, David; Skardal, Aleksander; Venere, Monica
  • Licensing Officer: Willson, Christopher

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian; Schelhorn, Jean
  • Licensing Officer: Dahlman, Jason "Jay"

Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

Show More Technologies

Loading icon